PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Rimegepant 25 MG
Drug: Rimegepant 75 MG

First Posted Date: 2022-06-01

Last Posted Date: 2024-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 803

Registration Number: NCT05399459

Locations: 🇯🇵
Konan Medical Center, Kobe-shi, Hyōgo, Japan
🇯🇵
Fujitsu Clinic, Nakahara, Kawasaki, Kanagawa, Japan
🇯🇵
Suzuki Kei Yasuragi clinic, Tachikawa-city, Tokyo, Japan

and more 61 locations

Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)

Phase 3

Active, not recruiting

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Rimegepant

First Posted Date: 2022-06-01

Last Posted Date: 2024-12-18

Lead Sponsor: Pfizer

Target Recruit Count: 496

Registration Number: NCT05399485

Locations: 🇯🇵
Higashi Sapporo Neurology and Neurosurgery Clinic, Sapporo-shi, Hokkaido, Japan
🇯🇵
Shinagawa Strings Clinic, Minato-ku, Tokyo, Japan
🇯🇵
Fukuuchi Pain Clinic, Shinjuku-ku, Tokyo, Japan

and more 47 locations

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Completed

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: avelumab
Drug: axitinib

First Posted Date: 2022-05-27

Last Posted Date: 2023-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 130

Registration Number: NCT05394493

Locations: 🇬🇧
Pfizer Ltd, Sandwich, Kent, United Kingdom

A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis

Recruiting

Conditions: Dermatitis, Atopic

First Posted Date: 2022-05-25

Last Posted Date: 2024-07-23

Lead Sponsor: Pfizer

Target Recruit Count: 3000

Registration Number: NCT05391061

Locations: 🇰🇷
Pfizer Tower, Seoul, Korea, Republic of

A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: CIBINQO

First Posted Date: 2022-05-24

Last Posted Date: 2023-08-29

Lead Sponsor: Pfizer

Target Recruit Count: 1200

Registration Number: NCT05387980

Locations: 🇯🇵
Pfizer Local Country Office, Tokyo, Japan

A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19

Phase 1

Recruiting

Conditions: COVID-19

Interventions: Drug: nirmatrelvir
Drug: ritonavir

First Posted Date: 2022-05-23

Last Posted Date: 2024-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 49

Registration Number: NCT05386472

Locations: 🇺🇸
University of Alabama at Birmingham Women & Infant Center, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham/Center for Women's Reproductive Health, Birmingham, Alabama, United States
🇺🇸
Abby's Research institute, Phoenix, Arizona, United States

and more 28 locations

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Phase 1

Active, not recruiting

Conditions: Metastatic HER2+ Advanced Breast Cancer
Breast Neoplasms
Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Colorectal Cancer

Interventions: Drug: Tucatinib

First Posted Date: 2022-05-19

Last Posted Date: 2024-10-29

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT05382364

Locations: 🇨🇳
Harbin Medical University Cancer Hospital-oncology of department ( Site 0010), Harbin, Heilongjiang, China
🇨🇳
Hunan Cancer Hospital-Digestion and Urology ( Site 0008), Changsha, Hunan, China
🇨🇳
Jilin Cancer Hospital-oncology department ( Site 0007), Changchun, Jilin, China

and more 2 locations

This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Inflectra

First Posted Date: 2022-05-17

Last Posted Date: 2024-04-12

Lead Sponsor: Pfizer

Target Recruit Count: 255

Registration Number: NCT05375942

Locations: 🇺🇸
Pfizer, Collegeville, Pennsylvania, United States

A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Abrocitinib 100 mg
Drug: Abrocitinib 200 mg

First Posted Date: 2022-05-17

Last Posted Date: 2024-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 189

Registration Number: NCT05375929

Locations: 🇮🇳
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳
All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳
S. P. Medical College & A. G. Hospitals, Bikaner, Rajasthan, India

and more 12 locations

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Phase 2

Completed

Conditions: Plaque Psoriasis
Atopic Dermatitis

Interventions: Drug: PF-07038124 ointment 0.01%
Drug: PF-07038124 ointment 0.06%
Drug: PF-07038124 ointment 0.03%
Drug: Vehicle ointment

First Posted Date: 2022-05-17

Last Posted Date: 2024-10-02

Lead Sponsor: Pfizer

Target Recruit Count: 263

Registration Number: NCT05375955

Locations: 🇺🇸
Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
🇨🇦
Lynderm Research Inc., Markham, Ontario, Canada
🇺🇸
Renaissance Research and Medical Group, Cape Coral, Florida, United States

and more 33 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy